ABL Bio to Hold Overseas NDR in Hong Kong and Singapore
Enhancing Shareholder Value Through Ongoing Global NDRs
ABL Bio, a company specializing in bispecific antibodies, announced on January 23 that it will hold overseas non-deal roadshows (NDR) in Hong Kong and Singapore from February 2 to 4 (local time).
This NDR is organized to share ABL Bio's bispecific antibody platform, the current status of its major pipelines, and its mid- to long-term business strategies with overseas institutional investors. The company aims to expand its global investor network and enhance shareholder value by attracting foreign capital.
ABL Bio is expanding its pipeline with a focus on the BBB shuttle platform 'Grabody-B' and the 4-1BB-based immuno-oncology platform 'Grabody-T.' Grabody-B, a technology targeting IGF1R, has been licensed out to GSK and Eli Lilly. The Parkinson's disease treatment ABL301 was licensed to Sanofi and has completed Phase 1 clinical trials in the United States.
Among the Grabody-T-based pipeline candidates?ABL111, ABL503, and ABL103?ABL111 demonstrated significant efficacy and safety in a Phase 1b clinical trial for gastric cancer patients in combination with nivolumab and a chemotherapeutic agent.
ABL Bio's first bispecific antibody, ABL001, is currently undergoing global Phase 2/3 clinical trials as a second-line treatment for cholangiocarcinoma by Compass Therapeutics. The company plans to release key clinical indicators, including progression-free survival and overall survival, in the first half of this year.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Sanghoon, CEO of ABL Bio, stated, "Following our NDR in the United States, we will continue to engage with overseas investors in Hong Kong and Singapore," adding, "Through ongoing global NDRs, we aim to enhance both our corporate value and shareholder value."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.